ARTICLE | Company News
MedImmune, Compugen in antibody deal
April 6, 2018 8:59 PM UTC
Compugen Ltd. (NASDAQ:CGEN; Tel Aviv:CGEN) granted the MedImmune LLC subsidiary of AstraZeneca plc (LSE:AZN; NYSE:AZN) an exclusive license to develop multiple bi-specific and multi-specific immuno-oncology antibody products.
Compugen will receive $10 million up front and will be eligible for up to $200 million in milestones for the first product; if additional products are developed, Compugen will be eligible for additional milestones. The company is also eligible for royalties. ...